Posted by Michael Wonder on 05 Nov 2021
AstraZeneca Canada files for Health Canada authorisation of AZD7442 for prevention of COVID-19
3 November 2021 - AstraZeneca Canada has initiated a rolling review new drug submission with Health Canada for authorization of AZD7442, its long-acting antibody combination, for prevention of symptomatic COVID-19.
If granted, AZD7442 would be the first LAAB to receive Health Canada authorization for COVID-19 prevention.
